Clinical Trials Browser

Phase 2 × Has announcements × Carcinoma, Non-Small-Cell Lung × Clear all

NCT04484142 2026-03-17

Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)

Phase 2 Completed

137 enrolled 9 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT02568267 2026-03-06

STARTRK-2

Phase 2 Active not recruiting

534 enrolled 1 FDA

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT04395677 2026-02-06

A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene

Phase 2 Active not recruiting

173 enrolled 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04919811 2026-01-07

TRUST-II

Phase 2 Active not recruiting

217 enrolled 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT02864992 2025-12-23

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

Phase 2 Active not recruiting

337 enrolled 13 charts 2 FDA

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT04644237 2025-11-21

DESTINY-LUNG02

Phase 2 Completed

152 enrolled 22 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03915951 2025-11-17

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Phase 2 Completed

98 enrolled 18 charts 1 FDA

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT02576431 2025-11-12

NAVIGATE

Phase 2 Completed

215 enrolled 3 FDA

BreastDermatologicGastrointestinalHead & NeckSarcomaThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Salivary Gland Neoplasms, Sarcoma, Thyroid Neoplasms, Colorectal Neoplasms

NCT03539536 2025-11-05

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

270 enrolled 1 FDA

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT03505710 2025-05-30

DESTINY-Lung01

Phase 2 Terminated

181 enrolled 17 charts 1 FDA

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT02912949 2025-04-29

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

Phase 2 Active not recruiting

250 enrolled 1 FDA

GastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms

NCT02414139 2024-03-20

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Phase 2 Completed

373 enrolled 34 charts 3 FDA

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT01336634 2022-04-04

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

Phase 2 Completed

177 enrolled 19 charts 1 FDA

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00525148 2016-09-16

LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations

Phase 2 Completed

129 enrolled 18 charts 1 FDA

Carcinoma, Non-Small-Cell Lung